Gelonghui, April 18 | Meikang Biotech (300439.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,886 billion yuan, a year-on-year decrease of 24.23%; net profit attributable to shareholders of listed companies was 255 million yuan, up 29.23% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 196 million yuan, up 14.89% year on year; basic income per share was 0.67 yuan; it plans to distribute a cash dividend of 1.34 yuan (tax included) to all shareholders for every 10 shares.